Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

L’Oreal

- PMLiVE

Dendreon wins IQWiG U-turn for its immunotherapy Provenge

New data for its troubled cancer drug convinces German HTA body of its added benefit

- PMLiVE

Valeant raises offer for Salix; rival Endo bows out

Has increased bid to $173 per share in cash

National Institute for Health and Care Excellence NICE logo

Good NICE news for Pfizer, but Dendreon drug rejected

Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not

- PMLiVE

Valeant swoops on Salix with $10bn takeover deal

Firm will also absorb Salix’s $4.6bn debt, adding to its existing $15bn

- PMLiVE

Valeant and Shire said to be evaluating potential Salix bids

Valeant currently in final stages of Provenge acquisition

- PMLiVE

Valeant lead bidder for troubled Dendreon

Willing to pay $296m for company behind prostate cancer vaccine Provenge

- PMLiVE

NICE says cost of Dendreon’s cancer vaccine is too high

Another blow as the bankrupt company goes to auction next month

- PMLiVE

Dendreon to go to auction without initial bidder

A selection for a bidder wanting to pay the minimum price has not been made

- PMLiVE

Actavis to buy Allergan for $66bn

Ends Valeant’s pursuit of Botox maker

- PMLiVE

Allergan ‘close’ to $60bn takeover agreement with Actavis

If successful the negotiations would scupper Valeant's hostile bid

- PMLiVE

Dendreon files for bankruptcy protection

Follows poor sales of cancer vaccine Provenge

- PMLiVE

Actavis ‘considering’ white knight bid for Allergan

Wall Street Journal says Irish pharma company set to challenge Valeant's bid

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links